Pneumococcal Vaccine

Pneumococcal vaccine refers to a group of vaccines that help protect against infections caused by Streptococcus pneumoniae, a bacterium responsible for pneumonia, meningitis, bloodstream infections and certain ear infections. These vaccines include pneumococcal conjugate vaccines (PCVs) and pneumococcal polysaccharide vaccines (PPSVs). Conjugate vaccines link pneumococcal capsular polysaccharides to a carrier protein, helping the immune system develop an effective antibody response and immune memory. Polysaccharide vaccines contain purified capsular polysaccharide antigens and stimulate an immune response against the serotypes included in the formulation. Available vaccines differ in the number and types of pneumococcal serotypes they cover.

Pneumococcal vaccines are preventive medicines rather than treatments for an existing bacterial infection. They are administered by injection, generally intramuscularly, although certain polysaccharide formulations may also be given subcutaneously according to product instructions. Vaccination is particularly important for young children, older adults and people with conditions that increase the risk of severe pneumococcal disease. The appropriate product, timing and number of doses depend on age, medical history, previous vaccinations, immune status and national immunisation recommendations. Although vaccination substantially reduces the risk of disease caused by covered serotypes, it does not prevent every pneumococcal infection or all causes of pneumonia.

Pneumococcal vaccines were developed to reduce the burden of disease caused by Streptococcus pneumoniae. Early polysaccharide vaccines targeted multiple pneumococcal serotypes, while later conjugate vaccines were designed to generate stronger immune responses and immune memory, particularly in infants and young children. In the United States, the FDA initially approved Pneumovax 23 in 1977, and later licensed pneumococcal conjugate vaccines, including PCV13 in 2010, PCV15 in 2021, PCV20 in 2021 and PCV21 in 2024 for specified populations and indications. In Europe, the EMA authorised Prevenar 13 in 2009 and subsequently assessed higher-valency conjugate vaccines, including Apexxnar, which received European Union authorisation in 2022. The World Health Organization has recommended pneumococcal conjugate vaccination for childhood immunisation programmes, with schedules adapted to national requirements. Approval dates and indications differ by vaccine formulation and country; current local product information and immunisation guidelines should be consulted when selecting a vaccine.

Pneumococcal vaccines are used to prevent pneumococcal disease, including invasive infections such as meningitis and bacteraemia, as well as pneumonia and, for certain vaccine formulations and age groups, acute otitis media. Routine childhood vaccination is recommended in many national immunisation programmes. Older adults and people with risk factors, including chronic heart, lung, liver or kidney disease, diabetes, immunocompromising conditions, asplenia or certain other medical conditions, may also require vaccination. Pneumococcal conjugate vaccines and polysaccharide vaccines are not interchangeable in every schedule, and recommendations depend on the formulation, age, previous vaccination history and local guidance. Some individuals require only one dose of a particular vaccine, while others may need sequential vaccination or additional doses according to their risk category and immunisation history. Pneumococcal vaccination does not replace appropriate diagnosis and antibiotic treatment when a bacterial infection is already present.

Pneumococcal vaccines are administered by injection, usually intramuscularly. Certain polysaccharide formulations may also be administered subcutaneously when permitted by the product information. For children, conjugate vaccines are given according to the recommended national immunisation schedule, which may use a three-dose or four-dose primary and booster schedule depending on the vaccine, age at initiation and programme. Adults generally receive a single dose of an appropriate conjugate vaccine or a sequential regimen involving a conjugate vaccine and PPSV23, depending on the product, previous vaccination and applicable recommendations. Some adults with specific medical risks may require additional vaccination according to local guidance. The timing of subsequent doses depends on the vaccine combination and interval requirements; doses should not be repeated automatically without reviewing the vaccination record. Treatment duration is not applicable because these are preventive vaccines. Healthcare professionals should verify the product, age eligibility, route, dose, contraindications and storage requirements before administration.

Common side effects of pneumococcal vaccines include pain, redness, swelling or tenderness at the injection site. Some recipients experience fever, fatigue, headache, muscle aches, irritability, reduced appetite or temporary changes in sleep, particularly in young children. These reactions are usually mild to moderate and resolve within a few days. The frequency and pattern of adverse effects vary according to the vaccine formulation, age and individual health status. When pneumococcal vaccines are administered alongside other routine vaccines, some reactions may be associated with either vaccine. Most recipients do not experience serious complications. Persistent fever, worsening symptoms or unexpected reactions should be assessed by a healthcare professional, especially in infants, older adults and people with underlying medical conditions.

Serious adverse events following pneumococcal vaccination are uncommon but may include anaphylaxis or other severe allergic reactions to a vaccine component. Vaccination should not be administered to individuals with a known severe allergic reaction to a previous dose or a relevant component of the specific vaccine. Moderate or severe acute illness may warrant postponement until the person's condition improves, although minor illnesses are not generally a reason to delay vaccination. Premature infants may require particular consideration because some conjugate vaccine product information includes a risk of apnoea following vaccination in this population. People with a history of severe reactions to vaccines should be assessed before another dose is given. Pneumococcal vaccines cannot prevent disease caused by every pneumococcal serotype, and vaccination does not guarantee complete protection. Suspected anaphylaxis requires immediate emergency treatment. Decisions about further doses following a serious reaction should be made by a qualified healthcare professional.

Before vaccination, healthcare professionals should review previous pneumococcal vaccinations, known allergies, immune status, underlying medical conditions and any history of serious vaccine reactions. Immunocompromised individuals may develop a weaker immune response, although vaccination may be particularly important for preventing severe disease in these patients. The timing and effectiveness of vaccination may be affected by immunosuppressive treatments, chemotherapy or other therapies that alter immune function. Pneumococcal vaccines may be administered with other indicated vaccines at the same visit when permitted by the relevant product information, using separate injection sites and appropriate administration procedures. Pregnancy-related recommendations depend on the specific vaccine and the individual's clinical risk; vaccination should follow current national guidance and product information. Classic drug interactions are generally limited because vaccines are not conventional medicines metabolised through drug-processing pathways. However, immunosuppressive medicines may reduce vaccine responses, and previous vaccine doses can affect the recommended timing of subsequent doses. Live-vaccine precautions do not generally apply to pneumococcal vaccines because the available formulations are non-live vaccines.

Verify the patient's age, clinical risk factors, previous pneumococcal vaccine history and applicable national recommendations before selecting a formulation. Distinguish between conjugate vaccines and polysaccharide vaccines because their indications, immune responses and recommended sequences differ. Check the product label for the correct dose, route, storage conditions, expiry date and age eligibility. Maintain the recommended cold chain and avoid freezing products unless the specific product information states otherwise. Screen for severe allergic reactions to previous doses or relevant components, and ensure that appropriate emergency treatment for anaphylaxis is available. Counsel patients and caregivers about expected injection-site reactions, mild fever and other temporary symptoms, along with warning signs that require urgent medical assessment. Document the vaccine name, formulation, batch number, dose, administration date and injection site. For patients receiving immunosuppressive treatment or those with complex medical histories, coordinate vaccination timing with the treating specialist. Review the vaccination record before recommending additional doses, and follow the current national immunisation schedule rather than applying one universal regimen to all patients.